Watson Pharmaceuticals (WPI +1.8%) gains after being upgraded to Conviction Buy on valuation at...

|By:, SA News Editor

Watson Pharmaceuticals (WPI +1.8%) gains after being upgraded to Conviction Buy on valuation at Goldman, citing its premium growth and likely tentative approval for Lidoderm. The firm keeps its price target at $87.